Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (22392)	6/17/1998 5:48:00 PM
From: WTDEC	Read Replies (3) \| Respond to of 32384

'The BLA was submitted on December 9, 1997, and the complete review letter is dated June 9, 1998. Upon issuance of the letter, the review clock is suspended and is not reactivated until all deficiencies have been addressed by Seragen. The letter identified certain deficiencies in the application related to safety, efficacy, manufacturing and product characterization. ''We are pleased with the timeliness of the FDA's review of our application,'' said Seragen's president and chief technology officer, Jean Nichols, Ph.D. ''We look forward to continuing to work closely with the agency to address the issues outlined in the letter.'' ' Sounds like a serious delay to me. Henry, any sense of what this is all about?